February 14, 2017 / 11:58 AM / 6 months ago

BRIEF-Acorda Therapeutics reports Q4 adj eps of $0.05

Feb 14 (Reuters) - Acorda Therapeutics Inc :

* Acorda provides financial and pipeline update for fourth quarter and year end 2016

* Sees FY 2017 ampyra sales $535 million to $545 million

* Q4 revenue $140.6 million versus I/B/E/S view $138.7 million

* Q4 non-GAAP earnings per share $0.05

* Q4 GAAP loss per share $0.07

* Q4 earnings per share view $0.10 -- Thomson Reuters I/B/E/S

* Research and development expenses for full year 2017 are expected to be $185-$195 million.

* Ampyra 2017 net sales guidance of $535-$545 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below